Trials / Recruiting
RecruitingNCT06568094
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
An Open, Multicenter Phase Ib/II Study on the Safety, Tolerability and Efficacy of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-5041 tablets | HRS-5041 tablets |
| DRUG | Abiraterone Acetate tablets（II） | Abiraterone Acetate tablets（II） |
| DRUG | Prednisone Acetate tablets | Prednisone Acetate tablets |
| DRUG | Docetaxel Injection | Docetaxel Injection |
| DRUG | HRS-1167 tablets | HRS-1167 tablets |
| DRUG | SHR2554 tablets | SHR2554 tablets |
Timeline
- Start date
- 2024-09-25
- Primary completion
- 2026-06-01
- Completion
- 2027-06-01
- First posted
- 2024-08-23
- Last updated
- 2025-12-31
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06568094. Inclusion in this directory is not an endorsement.